

52.


CLAIMS

1. A method of inhibiting dynamin-dependent endocytosis in cells, the method comprising treating the cells with an effective amount of a compound of formula I, or a physiologically acceptable salt thereof, wherein

5

**Formula I**

M and M' are each independently a moiety of formula II and are the same or different, and Sp is a spacer;

**Formula II**

10

V is C or CH;

W is CH or a linker group; and

Y is hydrogen, cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy, sulfur, or an unsubstituted C₁-C₃ group or C₁-C₃ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur; or

15

W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic or carbocyclic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3 heteroatoms selected from O, N and S, and the heterocyclic or carbocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy, sulfur, or an unsubstituted C₁-C₃ group or C₁-C₃ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur; and

20

R is CH₂R', CXR' or CHX'R';

25

X is O or S;

X' is cyano, nitro, amino, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy, or an unsubstituted C₁-C₃ group or C₁-C₃ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur;

30

R' is NH, O or S bonded to the spacer; and

53.

Z is selected from:

(a) an unsubstituted heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms selected from O, N and S;

5 (b) an unsubstituted carbocyclic group consisting of one or two rings independently having 5 or 6 ring members;

(c) a heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms selected from O, N and S wherein the heterocyclic group has one or more substituents 10 independently selected from:

(i) nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and

15 (ii) a C₁-C₂ alkyl or C₁-C₂ alkenyl group with at least one substituent selected from nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and

(d) a carbocyclic group consisting of one or two rings independently having 5 or 6 ring members, and at least two substituents when W is CH or a linker group or W, V and Y form an unsubstituted carbocyclic group, or at least one substituent when W, V and Y form a heterocyclic group, independently 20 selected from:

(i) nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and

25 (ii) a C₁-C₂ alkyl or C₁-C₂ alkenyl group with at least one substituent selected from nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl;

wherein when Z of one of M or M' is selected from (b), Z of the other of M or M' is selected from (a), (c) or (d).

2. A method according to claim 1 wherein:

30 V is C;

W is CH;

Y is hydrogen, cyano, nitro, amino, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur; or

35 W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic

54.

or carbocyclic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3 heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur; and

R is CH₂R', CXR' or CHX'R';

X is O or S; and

X' is cyano, nitro, amino, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulphur.

3. A method according to claim 2 wherein:

Y is cyano, nitro, amino, carboxy, hydroxy, sulfhydryl, thiocarboxy, or a C₁-C₂ group substituted with a group selected from cyano, nitro, amino, hydroxy, sulfhydryl, carboxy and thiocarboxy;

W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic or carboxylic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3 heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, amino, hydroxy, sulfhydryl, carboxy and thiocarboxy, or a C₁-C₂ group substituted with a group selected from cyano, nitro, amino, hydroxy, sulfhydryl, carboxy and thiocarboxy; and

R is CXR'.

25 4. A method according to any one of claims 1 to 3 wherein Z is selected from:

(i) a heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms independently selected from O, N and S;

(ii) a heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms independently selected from O, N and S, wherein the heterocyclic group has one or more substituents independently selected from nitro, NH, halo, cyano, amino, hydroxy, carboxy, oxo, sulfur, and C₁-C₂ alkoxy; and

(iii) an carbocyclic group consisting of one or two rings independently

55.

having 5 or 6 ring members, and at least two substituents independently selected from nitro, NH, amino, halo, cyano, hydroxy, carboxy, oxo, sulfur and C₁-C₂ alkoxy.

5. A method according to any one of claims 1 to 4 wherein Z of at least one of M and M' is other than a 2,3-disubstituted carboxycyclic group.

5 6. A method according to any one of claims 1 to 5 wherein Z of at least one of M and M' comprises:

at least two substituents in ortho positions relative to one another or in adjacent substitution positions, when the Z group is selected from (d) and W is CH or a C₁-C₃ linker group; or

10 the, or one of, the substituents on a carbon atom adjacent to the, or one of the, heteroatom(s) when the Z group is a heterocyclic group selected from (c); or

when W, V and Y are cyclised forming a heterocyclic ring fused with Z, the, or one of, the substituents on a carbon atom spaced at least one bond length from the heterocyclic ring.

15 7. A method according to any one of claims 1 to 6 wherein when the Y substituent of one of M or M' is hydrogen, the Y substituent of the other of M and M' is other than hydrogen.

8. A method according to any one of claims 1 to 7 wherein W, V and Y form a 5 or 6 membered heterocyclic ring fused with Z.

20 9. A method according to claim 8 wherein the heterocyclic ring fused with Z forms a two ring heterocyclic group.

10. A method according to any one of claims 1 to 8 wherein Z comprises an aryl group consisting of one or two rings independently having 5 or 6 ring members, and at least two substituents independently selected from nitro, NH, amino, halo, cyano, hydroxy, carboxy, oxo, sulphur and C₁-C₂ alkoxy.

25 11. A method according to claim 10 wherein Z comprises an aryl group consisting of one ring having 6 ring members and at least two substituents independently selected from nitro, amino, halo, cyano, hydroxy, carboxy and C₁-C₂ alkoxy.

30 12. A method according to claim 11 wherein the aryl group has at least two substituents independently selected from nitro, amino, and hydroxy.


56.

13. A method according to any one of claims 1 to 8 wherein Z comprises a heterocyclic group having one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms selected from O, N and S, wherein the heterocyclic group has one or more substituents independently selected from nitro, NH, halo, cyano, amino, hydroxy, carboxy, oxo, sulphur and C₁-C₂ alkoxy.

5

14. A method according to claim 13 wherein the heterocyclic group has one or more substituents independently selected from nitro, amino and hydroxy.

15. A method according to any one of claims 1 to 5 wherein M and M' are each independently a moiety as follows:



10

wherein:

X is O or S;

Y is cyano, nitro, amino, halo, hydroxy, sulphydryl, carboxy, or thiocarboxy; or

R₁ and Y are cyclised forming a 5 or 6 membered substituted or unsubstituted

15 heterocyclic or carbocyclic ring, wherein the heterocyclic ring includes 1 or 2 heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur; and

20 R₂ to R₅ are independently hydrogen or a substituent independently selected from nitro, amino, halo, hydroxy, carboxy, sulphydryl, thiocarboxy, C₁-C₂ alkoxy and C₁-C₂ acyl; or

R₁ to R₅ are independently hydrogen or a substituent independently selected from nitro, amino, halo, hydroxy, carboxy, sulphydryl, thiocarboxy, halo, C₁-C₂ alkoxy and C₁-C₂ acyl; and

25 R is NH, O is S bonded to the spacer Sp; and

wherein at least one of M and M' is characterised in that, at least two of R₁ to R₅ are other than hydrogen and when R₁ to R₂ are other than hydrogen at least one of R₃ to R₅ is also other than hydrogen, or when R₁ and Y are cyclised, at least two of R₂

57.

to R₅ are other than hydrogen when R₁ and Y form an unsubstituted carbocyclic group or at least one of R₂ to R₅ is other than hydrogen when Y and R₁ form a heterocyclic group.

16. A method according claim 15 wherein R₁ to R₃ are other than hydrogen.
- 5 17. A method according to claim 15 wherein at least two of R₁ to R₅ are in ortho positions relative to one another.
18. A method according to claim 15 wherein at least one of M and M' has three substituents and wherein the substituents are adjacent to one another.
- 10 19. A method according to claim 18 wherein either R₁ to R₃ are other than hydrogen or R₂ to R₅ are other than hydrogen.
20. A method according to claim 15 wherein when at least one of R₁ to R₅ or R₂ to R₅ is halo, C₁-C₂ alkoxy or C₁-C₂ acyl, at least one other substituent is selected from nitro, amino, hydroxy, carboxy and thiocarboxy when R₁ and Y are cyclised and form a heterocyclic ring, or at least two other substituents are selected from nitro, amino, hydroxy, carboxy and thiocarboxy when R₁ and Y are not cyclised or form an unsubstituted carboxylic ring.
- 15 21. A method according to any one of claims 15 to 20 wherein Y is cyano, X is O and R is NH.
22. A method according to any one of claims 1 to 21 wherein M and M' are the same.
- 20 23. A method according to any one of claims 1 to 22 wherein the spacer Sp permits the compound to adopt a hairpin conformation.
24. A method according to any one of claims 1 to 23 wherein the spacer Sp comprises an unsubstituted alkane chain as follows:



- 25 wherein n is an integer of from 1 to 5.
25. A method according to any one of claims 1 to 24 wherein the compound of Formula I is a dimeric tyrphostin.

58.


26. A method of prophylaxis or therapeutic treatment of a disease or condition in a mammal mediated by dynamin-dependent endocytosis, the method comprising administering to the mammal an effective amount of a compound of Formula I, or a physiologically acceptable salt, or prodrug thereof, wherein:

5

M-Sp-M'

Formula I

M and M' are each independently a moiety of formula II and are the same or different, and Sp is a spacer;

**Formula II**

10 V is C or CH;
 W is CH or a linker group; and
 Y is hydrogen, cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl,
 carboxy, thiocarboxy, sulfur, or an unsubstituted C₁-C₃ group or C₁-C₃ group
 substituted with at least one group independently selected from cyano, nitro, NH,
 amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur; or
 W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic
 or carbocyclic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3
 heteroatoms selected from O, N and S, and the heterocyclic or carbocyclic ring, when
 substituted, has at least one substituent selected from cyano, nitro, NH, amino, oxo,
 halo, hydroxy, sulphydryl, carboxy, thiocarboxy, sulfur, or an unsubstituted C₁-C₃
 group or C₁-C₃ group substituted with at least one group independently selected from
 cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and
 sulfur; and
 R is CH₂R', CXR' or CHX'R';
 X is O or S;
 X' is cyano, nitro, amino, halo, hydroxy, sulphydryl, carboxy, thiocarboxy, or
 an unsubstituted C₁-C₃ group or C₁-C₃ group substituted with at least one group
 independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl,
 carboxy, thiocarboxy and sulfur;
 R' is NH, O or S bonded to the spacer; and
 Z is selected from:

59.

(a) an unsubstituted heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms selected from O, N and S;

5 (b) an unsubstituted carbocyclic group consisting of one or two rings independently having 5 or 6 ring members;

10 (c) a heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms selected from O, N and S wherein the heterocyclic group has one or more substituents independently selected from:

15 (i) nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and

20 (ii) a C₁-C₂ alkyl or C₁-C₂ alkenyl group with at least one substituent selected from nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and

25 (d) a carbocyclic group consisting of one or two rings independently having 5 or 6 ring members, and at least two substituents when W is CH or a linker group or W, V and Y form an unsubstituted carbocyclic group, or at least one substituent when W, V and Y form a heterocyclic group, independently selected from:

30 (i) nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and

(ii) a C₁-C₂ alkyl or C₁-C₂ alkenyl group with at least one substituent selected from nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl;

27. wherein when the Z group of one of M or M' is selected from (b), the Z group of the other of M or M' is selected from (a), (c) or (d).

27. A method according to claim 26 wherein:

V is C;

W is CH;

30 Y is hydrogen, cyano, nitro, amino, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur; or

35 W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic or carbocyclic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3

60.

heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur; and

R is CH₂R', CXR' or CHX'R';

X is O or S;

X' is cyano, nitro, amino, halo, hydroxy, sulphydryl, carboxy, thiocarboxy, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur; and

R' is NH, O or S bonded to the spacer.

28. A method according to claim 27 wherein:

Y is cyano, nitro, amino, carboxy, hydroxy, sulphydryl, thiocarboxy, or a C₁-C₂ group substituted with a group selected from cyano, nitro, amino, hydroxy, sulphydryl, carboxy and thiocarboxy;

W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic or carboxylic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3 heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, amino, hydroxy, sulphydryl, carboxy and thiocarboxy, or a C₁-C₂ group substituted with a group selected from cyano, nitro, amino, hydroxy, sulphydryl, carboxy and thiocarboxy; and

R is CXR'.

25 29. A method according to any one of claims 26 to 28 wherein Z of at least one of M and M' is other than a 2,3-disubstituted carbocyclic group.

30. A method according to any one of claims 26 to 29 wherein Z of at least one M and M' comprises:

at least two substituents ortho relative to one another or in adjacent substitution positions when the Z group is selected from (d) and W is CH or a C₁-C₃ linker group; or

the, or one of, the substituents on a carbon atom adjacent to the, or one of the, heteroatom(s) when the Z group is a heterocyclic group selected from (c); or


when W, V and Y are cyclised forming a heterocyclic ring fused with Z, the, or

61.

one of, the substituents on a carbon atom of Z spaced at least one bond length from the heterocyclic ring.

31. A method according to any one of claims 26 to 30 wherein when the Y substituent of one of M or M' is hydrogen, the Y substituent of the other of M and M' is other than hydrogen.

5 32. A method according to any one of claims 26 to 31 wherein M and M' are each independently a moiety as follows:



wherein:

10 X is O or S;

Y is cyano, nitro, amino, halo, hydroxy, sulfhydryl, carboxy, or thiocarboxy; or

R₁ and Y are cyclised forming a 5 or 6 membered substituted or unsubstituted heterocyclic or carbocyclic ring, wherein the heterocyclic ring includes 1 or 2 heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur; and

15 R₂ to R₅ are independently hydrogen or a substituent independently selected from nitro, amino, halo, hydroxy, carboxy, sulfhydryl, thiocarboxy, C₁-C₂ alkoxy and C₁-C₂ acyl; or

20 R₁ to R₅ are independently hydrogen or a substituent independently selected from nitro, amino, halo, hydroxy, carboxy, sulfhydryl, thiocarboxy, halo, C₁-C₂ alkoxy and C₁-C₂ acyl; and

25 R is NH, O is S bonded to the spacer Sp; and

 wherein at least one of M and M' is characterised in that, at least two of R₁ to R₅ are other than hydrogen and when R₁ to R₂ are other than hydrogen at least one of R₃ to R₅ is also other than hydrogen, or when R₁ and Y are cyclised, at least two of R₂ to R₅ are other than hydrogen when R₁ and Y form an unsubstituted carbocyclic group

62.

or at least one of R₂ to R₅ is other than hydrogen when Y and R₁ form a heterocyclic group.

33. A method according to claim 32 wherein R₁ to R₃ are other than hydrogen.
34. A method according to any one of claims 26 to 31 wherein at least two of R₁ to R₅ are in ortho positions relative to one another.
5
35. A method according to any one of claims 26 to 31 wherein at least one of M and M' has three substituents and wherein the substituents are adjacent to one another.
36. A method according to claim 33 wherein either R₁ to R₃ are other than hydrogen or R₂ to R₅ are other than hydrogen.
10
37. A method according to any one of claims 26 to 32 wherein when at least one of R₁ to R₅ or R₂ to R₅ is halo, C₁-C₂ alkoxy or C₁-C₂ acyl, at least one other substituent is selected from nitro, amino, hydroxy, carboxy and thiocarboxy when R₁ and Y are cyclised and form a heterocyclic ring, or at least two other substituents are selected from nitro, amino, hydroxy, carboxy and thiocarboxy when R₁ and Y are not cyclised
15 or form an unsubstituted carboxylic ring.
38. A method according to any one of claims 26 to 37 wherein Y is cyano, X is O and R is NH.
20
39. A method according to any one of claims 26 to 38 wherein M and M' are the same.
40. A method according to any one of claims 26 to 39 wherein the spacer Sp permits the compound to adopt a hairpin conformation.
25
41. A method according to any one of claims 26 to 40 wherein the compound of formula I is a dimeric tyrphostin.
42. A method according to any one of claims 26 to 41 wherein the disease or condition is selected from the group consisting of cancers, ophthalmologic diseases, immunodeficiency diseases, gastrointestinal diseases, pathogenic infections, kidney diseases, epilepsy, and neurological, neurodegenerative and nervous system diseases and conditions.
25
43. A method according to claim 42 wherein the neurological, neurodegenerative and nervous system diseases and conditions are selected from the group consisting of

63.

demyelinating diseases, Alzheimer's disease, Huntington's disease, Parkinson's disease and Lewy body diseases.

44. A method according to claim 42 wherein the disease or condition is epilepsy.

45. A method for prophylaxis or treatment of a disease or condition in a mammal
5 mediated by dynamin-dependent endocytosis, the method comprising administering to the mammal an effective amount of a dimeric tyrphostin which inhibits GTPase activity of dynamin, or an analogue, physiologically acceptable salt, or prodrug of the dimeric tyrphostin.

46. A method according to claim 45 wherein the dimeric tyrphostin comprises two
10 tyrphostin moieties linked together by a spacer moiety, wherein at least one of the tyrphostin moieties is a benzylidenemalonitrile moiety.

47. A method according to claim 46 wherein both of the tyrphostin moieties are
benzylidenemalonitrile moieties.

48. A method according to claim 46 or 47 wherein the tyrphostin moieties are the same.

15 49. A method according to any one of claims 45 to 48 wherein the dimeric tyrphostin comprises bis-tyrphostin.

20 50. A method according to any one of claims 45 to 49 wherein the disease or condition is selected from the group consisting of cancers, ophthalmologic diseases, immunodeficiency diseases, gastrointestinal diseases, pathogenic infections, kidney diseases, epilepsy, and neurological, neurodegenerative and nervous system diseases and conditions.

25 51. A method according to claim 50 wherein the neurological, neurodegenerative and nervous system diseases and conditions are selected from the group consisting of demyelinating diseases, Alzheimer's disease, Huntington's disease, Parkinson's disease and Lewy body diseases.

52. A method according to claim 50 wherein the disease or condition is epilepsy.

53. A method for identifying a dimeric tyrphostin or an analogue thereof with ability to inhibit GTPase activity of dynamin, the method comprising:

30 incubating the dimeric tyrphostin or analogue thereof with dynamin or a molecule having dynamin GTPase activity to provide test data; and

64.


determining whether the dimeric tyrophostin or analogue thereof inhibits the GTPase activity of dynamin on the basis of the test data.

54. Use of a dimeric tyrophostin or analogue thereof identified by a method as defined in claim 53 to inhibit dynamin-dependent endocytosis in cells.

5 55. A compound of Formula III or a physiologically acceptable salt, or prodrug thereof, wherein:

**Formula III**

M and M' are each independently a moiety of formula IV and are the same or different, and Sp is a spacer.

**Formula IV**

10

V is C or CH;

W is CH or a linker group; and

Y is hydrogen, cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy, sulfur, or an unsubstituted C₁-C₃ group or C₁-C₃ group

15

substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur; or

20

W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic or carbocyclic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3 heteroatoms selected from O, N and S, and the carbocyclic or the heterocyclic ring, when substituted, has at least one substituent selected from cyano, NH, nitro, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy, sulfur, or an unsubstituted C₁-C₃ group or C₁-C₃ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur; and

25

R is CH₂R', CXR' or CHX'R';

X is O or S;

X' is cyano, nitro, amino, halo, hydroxy, sulphydryl, carboxy, thiocarboxy, or an unsubstituted C₁-C₃ group or C₁-C₃ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur;

30

65.

R' is NH, O or S bonded to the spacer; and

Z is selected from:

(a) an unsubstituted heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms selected from O, N and S;

(b) an unsubstituted carbocyclic group consisting of one or two rings independently having 5 or 6 ring members;

(c) a heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms selected from O, N and S, wherein the heterocyclic group has one or more substituents independently selected from:

(i) nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and

(ii) a C₁-C₂ alkyl or C₁-C₂ alkenyl group with at least one substituent selected from nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and


(d) a carbocyclic group consisting of one or two rings independently having 5 or 6 ring members, and at least two substituents when W is CH or a linker group or W, V and Y form an unsubstituted carbocyclic group, or at least one substituent when W, V and Y form a heterocyclic group, independently selected from:

(i) nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl; and

(ii) a C₁-C₂ alkyl or C₁-C₂ alkenyl group with at least one substituent selected from nitro, NH, amino, cyano, halo, hydroxy, carboxy, oxo, sulfur, sulfhydryl, C₁-C₂ alkoxy and C₁-C₂ acyl;

wherein when Z of one of M or M' is selected from (b), Z of the other of M or M' is selected from (a), (c) or (d), and with the proviso that Z of at least one of M and M' is other than a benzyl group of formula IVa when R is CXR', X is O, R' is NH bonded to the spacer, V is C, W is CH, Y is cyano, and

66.



Formula IVa

R₁, R₂, and R₅ are H, and R₃ and R₄ are hydroxy; or

R₁ and R₅ are H, and R₂ to R₄ are hydroxy when Sp is a C₂-C₄ alkyl spacer; and
wherein Z' is a carbon atom bonded to W.

5 56. A compound according to claim 55 wherein:

V is C;

W is CH;

Y is hydrogen, cyano, nitro, amino, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur; or

W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic or carbocyclic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3 heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulfur; and

20 R is CH₂R', CXR' or CHX'R';

X is O or S; and

X' is cyano, nitro, amino, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy, or an unsubstituted C₁-C₂ group or C₁-C₂ group substituted with at least one group independently selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulfhydryl, carboxy, thiocarboxy and sulphur.

25 57. A compound according to claim 56 wherein:

Y is cyano, nitro, amino, carboxy, hydroxy, sulfhydryl, thiocarboxy, or a C₁-C₂

67.

group substituted with a group selected from cyano, nitro, amino, hydroxy, sulphydryl, carboxy and thiocarboxy;

W, V and Y form a 5 or 6 membered substituted or unsubstituted heterocyclic or carboxylic ring fused with Z, wherein the heterocyclic ring includes from 1 to 3 heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, amino, hydroxy, sulphydryl, carboxy and thiocarboxy, or a C₁-C₂ group substituted with a group selected from cyano, nitro, amino, hydroxy, sulphydryl, carboxy and thiocarboxy; and

R is CXR'.

10 58. A compound according to any one of claims 55 to 57 wherein Z is selected from:

- (i) a heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms independently selected from O, N and S;
- (ii) a heterocyclic group consisting of one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms independently selected from O, N and S, wherein the heterocyclic group has one or more substituents independently selected from nitro, NH, halo, cyano, amino, hydroxy, carboxy, oxo, sulfur, and C₁-C₂ alkoxy; and
- (iii) an carbocyclic group consisting of one or two rings independently having 5 or 6 ring members, and at least two substituents independently selected from nitro, NH, amino, halo, cyano, hydroxy, carboxy, oxo, sulfur and C₁-C₂ alkoxy.

15 59. A compound according to any one of claims 55 to 58 wherein Z of at least one of M and M' is other than a 2,3-disubstituted carboxycyclic group.


20 60. A compound according to any one of claims 55 to 59 wherein Z of at least one of M and M' comprises:

- at least two substituents in ortho positions relative to one another or in adjacent substitution positions, when the Z group is selected from (d) and W is CH or a C₁-C₃ linker group; or
- the, or one of, the substituents on a carbon atom adjacent to the, or one of the, heteroatom(s) when the Z group is a heterocyclic group selected from (c); or
- when W, V and Y are cyclised forming a heterocyclic ring fused with Z, the, or one of, the substituents on a carbon atom spaced at least one bond length from the heterocyclic ring.

68.

61. A compound according to any one of claims 55 to 60 wherein when the Y substituent of one of M or M' is hydrogen, the Y substituent of the other of M and M' is other than hydrogen.
62. A compound according to any one of claims 55 to 61 wherein W, V and Y form a 5 or 5 membered heterocyclic ring fused with Z.
63. A compound according to claim 62 wherein the heterocyclic ring fused with Z forms a two ring heterocyclic group.
64. A compound according to any one of claims 55 to 63 wherein Z comprises an aryl group consisting of one or two rings independently having 5 or 6 ring members, and at least two substituents independently selected from nitro, NH, amino, halo, cyano, hydroxy, carboxy, oxo, sulphur and C₁-C₂ alkoxy.
65. A compound according to claim 64 wherein Z comprises an aryl group consisting of one ring having 6 ring members and at least two substituents independently selected from nitro, amino, halo, cyanó, hydroxy, carboxy and C₁-C₂ alkoxy.
66. A compound according to claim 65 wherein the aryl group has at least two substituents independently selected from nitro, amino, and hydroxy.
67. A compound according to any one of claims 55 to 62 wherein Z comprises a heterocyclic group having one or two rings independently having 5 or 6 ring members including up to 3 heteroatoms selected from O, N and S, wherein the heterocyclic group has one or more substituents independently selected from nitro, NH, halo, cyano, amino, hydroxy, carboxy, oxo, sulphur and C₁-C₂ alkoxy.
68. A compound according to claim 67 wherein the heterocyclic group has one or more substituents independently selected from nitro, amino and hydroxy.
69. A compound according to any one of claims 55 to 59 wherein M and M' are each independently a moiety as follows:

69.



wherein:

X is O or S;

Y is cyano, nitro, amino, halo, hydroxy, sulphydryl, carboxy, or thiocarboxy; or

5 R₁ and Y are cyclised forming a 5 or 6 membered substituted or unsubstituted heterocyclic or carbocyclic ring, wherein the heterocyclic ring includes 1 or 2 heteroatoms selected from O, N and S, and the carbocyclic or heterocyclic ring, when substituted, has at least one substituent selected from cyano, nitro, NH, amino, oxo, halo, hydroxy, sulphydryl, carboxy, thiocarboxy and sulfur; and

10 R₂ to R₅ are independently hydrogen or a substituent independently selected from nitro, amino, halo, hydroxy, carboxy, sulphydryl, thiocarboxy, C₁-C₂ alkoxy and C₁-C₂ acyl; or

15 R₁ to R₅ are independently hydrogen or a substituent independently selected from nitro, amino, halo, hydroxy, carboxy, sulphydryl, thiocarboxy, halo, C₁-C₂ alkoxy and C₁-C₂ acyl; and

R is NH, O is S bonded to the spacer Sp; and

20 wherein at least one of M and M' is characterised in that, at least two of R₁ to R₅ are other than hydrogen and when R₁ to R₂ are other than hydrogen at least one of R₃ to R₅ is also other than hydrogen, or when R₁ and Y are cyclised, at least two of R₂ to R₅ are other than hydrogen when R₁ and Y form an unsubstituted carbocyclic group or at least one of R₂ to R₅ is other than hydrogen when Y and R₁ form a heterocyclic group.

70. A compound according claim 69 wherein R₁ to R₃ are other than hydrogen.
71. A compound according to claim 69 wherein at least two of R₁ to R₅ are in ortho positions relative to one another.
72. A compound according to claim 69 wherein at least one of M and M' has three substituents and wherein the substituents are adjacent to one another.

70.

73. A compound according to claim 72 wherein either R₁ to R₃ are other than hydrogen or R₂ to R₅ are other than hydrogen.

74. A compound according to claim 69 wherein when at least one of R₁ to R₅ or R₂ to R₅ is halo, C₁-C₂ alkoxy or C₁-C₂ acyl, at least one other substituent is selected from nitro, amino, hydroxy, carboxy and thiocarboxy when R₁ and Y are cyclised and form a heterocyclic ring, or at least two other substituents are selected from nitro, amino, hydroxy, carboxy and thiocarboxy when R₁ and Y are not cyclised or form an unsubstituted carboxylic ring.

75. A compound according to any one of claims 69 to 74 wherein Y is cyano, X is O and R is NH.

76. A compound according to any one of claims 55 to 75 wherein M and M' are the same.

77. A compound according to any one of claims 55 to 76 wherein the spacer Sp permits the compound to adopt a hairpin conformation.

78. A compound according to any one of claims 55 to 77 wherein the spacer Sp comprises an unsubstituted alkane chain as follows:

-CH₂(CH₂)_nCH₂- ...

wherein n is an integer of from 1 to 5.

79. A compound according to any one of claims 1 to 78 wherein the compound of Formula III is a dimeric typhostin.

80. A pharmaceutical composition comprising a compound as defined in any one of claims 55 to 58 together with a physiologically acceptable excipient, carrier or diluent.